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background:  Transcatheter aortic valve replacement (TAVR) is an effective treatment option in patients with symptomatic aortic stenosis 
who are at high risk for traditional surgical aortic valve replacement (SAVR). Several studies utilizing trial data or outside United States (US) 
registry data have addressed TAVR cost issues, although there is a paucity of cost data involving commercial cases in the US.
methods:  Using the Agency for Healthcare Research and Quality Healthcare Cost and Utilization Project-Nationwide Inpatient Sample 
(NIS) files, we performed a propensity score matched analysis of all commercial TAVR and SAVR cases performed in 2011. Overall hospital 
cost and length of stay (LOS), as well as procedural complications, were compared between the two matched cohorts. Differences in cost 
according to hospital specifics (geographic locale, academic/community, and size) were also analyzed.
results:  595 TAVR patients were matched to 1,785 SAVR patients in a 1:3 ratio.  There was no difference in mean ($181,912 versus 
$196,298) or median ($152,993 versus $155,974) hospital cost between TAVR and SAVR, (p=0.60).  The TAVR group had a significantly 
shorter hospital LOS than the SAVR group (mean of 9.76 days versus 12.01 days, p<0.001). There was no difference in post-procedural 
in-hospital death (3.4% vs. 2.5%, p=0.62) or stroke (2.6% vs. 3.1%, p=0.75) respectively between TAVR and SAVR, but TAVR patients 
were more likely to have bleeding complications (10.9% vs. 3.9%, p=0.004), vascular complications (2.5% vs. 0.2%, p=0.02), and require 
a pacemaker (15.1% vs. 7.6%, p=0.01). Both TAVR and SAVR were more costly in western hospitals, non-academic centers and smaller 
hospitals; however, there was no difference in cost between TAVR and SAVR within each hospital subgroup. 
Conclusion:  When analyzing in-hospital cost of propensity matched commercial TAVR and SAVR cases using the NIS data set, TAVR is 
an economically satisfactory alternative to SAVR and results in an approximately 2 day shorter LOS during the index hospitalization with 
similar major adverse events. 
